Document:

Exhibit 10.25

	 
	 
	Pathogenics, Inc.	99 Derby Street

Hingham, MA 02043, USA

Telephone: (781) 556-1090

Fax: (781) 925-8665

www.pathogenics.com

VIA FACSIMILE

May 15, 2007

Donald C. Fresne, Chairman & CEO

Egenix, Inc.

69 North Tower Hill Road

P.O. Box L

Millbrook, NY 12545

Re:	     Termination of Merger of Egenix, Inc. with and into Pathogenics, Inc.

Dear Mr. Fresne:

     The purpose of this letter is to set forth the mutual
agreement of Egenix, Inc. and Pathogenics, Inc. to terminate the Amended and Restated Agreement and Plan of
Merger dated as of November 28, 2006 in accordance with the provisions of Section 8.1(a) thereof. Concurrently
with the execution of this letter, Pathogenics, Inc. will execute and deliver to Egenix, Inc. the form of Release
attached as Schedule A hereto, and Egenix, Inc. will execute and deliver to Pathogenics, Inc. the form of Release
attached as Schedule B hereto.  Except as set forth in the Release to be delivered by Egenix, Inc. to Pathogenics,
Inc., from and after the date of this letter, neither party hereto shall have any obligation or liability to the other.  

     If the foregoing is acceptable, please so indicate by executing one copy
of this letter in the space provided and returning it to the undersigned along with the Release in the form of Schedule B.

	
 	
Pathogenics, Inc.	
	 

	
	 

	
	 		
By: 		
 /s/ Frederic P. Zotos	
	 		 		

	 		 		
Frederic P. Zotos, Esq.,	
	 		 		
President and Chief Executive Officer	
	 	 	
 
	
Accepted this 15th day of May, 2007		 	
 

	
Egenix, Inc.		
 
	
 	
 	
 
	
 	
 	
 
	
By: 		
 /s/ Donald C. Fresne		
 
	 		
	 
	 		
Donald C. Fresne		
 
	 		
Chairman and Chief Executive Officer		
 
	 	
 	
 
	 	
 	
 

SCHEDULE A

RELEASE

     PATHOGENICS, INC. (“Releasor”), a Delaware
corporation, in consideration of the receipt from Egenix, Inc. (“Egenix”), a Delaware corporation, of the payment of good and valuable
consideration, receipt and sufficiency of which payment are hereby acknowledged, hereby releases and discharges Egenix and all of its
past and present officers, directors, employees, shareholders, agents, attorneys, accountants, consultants, successors, assigns and
affiliates, and each of them (collectively called the “Releasees”), from all actions, causes of action, suits, debts, dues, sums of
money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses,
damages, judgments, extents, executions, claims and demands whatsoever, whether actual or inchoate, at law, in admiralty or in equity
(collectively, “Claims”) which Releasor, its respective shareholders, officers, directors, affiliates, administrators, successors and
assigns, or any of them, ever had or now have against the Releasees, or any of them, with respect to any act, event or omission which
has occurred at any time prior to and including the date of execution of this Release; provided, however, that the foregoing release
does not relieve Egenix of its obligation to make payment on that certain Promissory Noted dated November 28, 2006 in the original principal
amount of $140,705 from Egenix to Releasor.

     This Release may not be modified, amended or terminated, or the provisions hereof
waived, other than in a written instrument executed by Releasor and Egenix.

     This Release shall be construed and enforced in accordance with, and governed
by, the laws of the State of New York.

     
IN WITNESS WHEREOF, Releasor caused this release to be executed by a duly authorized officer on the 15th day of May, 2007.

	
 		 		
PATHOGENICS, INC.	
	 

	
	 

	
	 		 		
By: /s/ Frederic P. Zotos	
	 		 		

	 		 		
Frederic P. Zotos, Esq.	
	 		 		
President and Chief Executive Officer	

STATE OF ____________)

                        
                      
              ) ss:.

COUNTY OF ___________)

On the       day of                 in the year
2007, before me, the undersigned, personally appeared                 
                               , personally known to me or proved to me on the basis of
satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he executed
the same in his capacity, and that by his signature on the instrument, the individual, or the person upon behalf of which the individual
acted, executed the instrument.

	 	 	 
	 	
 	
 
	 	
 	

	 	
 	
Notary Public
	 	
 	
 

2

SCHEDULE B

RELEASE

     EGENIX, INC. (“Releasor”), a Delaware
corporation, in consideration of the receipt from Pathogenics, Inc. (“Pathogenics”), a Delaware corporation, of the payment
of good and valuable consideration, receipt and sufficiency of which payment are hereby acknowledged, hereby releases and
discharges Pathogenics and all of its past and present officers, directors, employees, shareholders, agents, attorneys,
accountants, consultants, successors, assigns and affiliates, and each of them (collectively called the “Releasees”),
from all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties,
covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions,
claims and demands whatsoever, whether actual or inchoate, at law, in admiralty or in equity (collectively, “Claims”) which
Releasor, its respective shareholders, officers, directors, affiliates, administrators, successors and assigns, or any of them,
ever had or now have against the Releasees, or any of them, with respect to any act, event or omission which has occurred at any
time prior to and including the date of execution of this Release.

     This Release may not be modified, amended or terminated,
or the provisions hereof waived, other than in a written instrument executed by Releasor and Pathogenics.

     This Release shall be construed and enforced in accordance with, and governed by,
the laws of the State of New York.

     
IN WITNESS WHEREOF, Releasor caused this release to be executed by a duly authorized officer on the 15th day of May, 2007.

	
 		 		
EGENIX, INC.	
	 

	
	 

	
	 		 		
By: /s/ Donald C. Fresne	
	 		 		

	 		 		
Donald C. Fresne	
	 		 		
Chairman and Chief Executive Officer	

STATE OF ____________)

                        
                      
              ) ss:.

COUNTY OF ___________)

On the       day of                 in the year
2007, before me, the undersigned, personally appeared                 
                               , personally known to me or proved to me on the basis of
satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he executed
the same in his capacity, and that by his signature on the instrument, the individual, or the person upon behalf of which the individual
acted, executed the instrument.

	 	 	 
	 	
 	
 
	 	
 	

	 	
 	
Notary Public
	 	
 	
 

3Exhibit 4.1

                          FIRST SUPPLEMENTAL INDENTURE

         THIS FIRST  SUPPLEMENTAL  INDENTURE  (this  "Supplemental  Indenture"),
dated as of May 15,  2007,  is entered  into by and among  Electroglas,  Inc., a
Delaware  corporation  (the  "Company"),   Electroglas  International,  Inc.,  a
Delaware  corporation (the  "Guarantor") and The Bank of New York Trust Company,
N.A., as trustee under the indenture referred to below (the "Trustee").

                               W I T N E S S E T H

         WHEREAS, the Company, the Guarantor and the Trustee are parties to that
certain  Indenture dated as of March 23, 2007 (the  "Indenture"),  providing for
the issuance by the Company of its 6.25% Convertible Senior Subordinated Secured
Convertible Notes due 2027 (the "Notes");

         WHEREAS,  Section 11.1 of the Indenture provides that the Company, when
authorized by a resolution of its Board of Directors, and the Trustee, may enter
into a supplemental  indenture without notice to or the consent of any Holder to
add to the covenants, restrictions or conditions as the Board of Directors shall
consider to be for the benefit of the holders of Notes;

         WHEREAS,  the Board of Directors of the Company  considers  the changes
herein to be for the benefit of the holders of Notes; and

         WHEREAS,  all other acts and things necessary to make this Supplemental
Indenture a valid, binding and enforceable  instrument and all of the conditions
and  requirements set forth in Section 9.02 of the Indenture have been performed
and fulfilled and the execution and delivery of this Supplemental Indenture have
been in all respects duly authorized.

         NOW,  THEREFORE,  in consideration of the premises and  notwithstanding
any provisions of the Indenture which, absent this Supplemental Indenture, might
operate to limit such action,  the parties  have  executed  and  delivered  this
Supplemental Indenture,  and the Company does hereby covenant and agree with the
Trustee for the benefit of the Holders,  from time to time,  of the Notes issued
under the Indenture, as follows:

                                    AGREEMENT

         1. Capitalized Terms.  Capitalized terms used herein without definition
shall have the meanings assigned to them in the Indenture.

         2. Amendment and  Restatement of Second  Paragraph of Section 16.1. The
second paragraph of Section 16.1 of the Indenture is hereby amended and restated
in its entirety to read as follows:

                  "In  addition,  Notes shall be purchased by the Company at the
         option of the holder on March 26, 2011, March 26, 2015, March 26, 2016,
         March 26,  2019,  March  26,  2021 and March  26,  2023  (each,  also a
         "Repurchase Date"), at the Repurchase Price."

<PAGE>

         3. Amendment and Restatement of Second Sentence of Section 16.2(a). The
second  sentence  of Section  16.2(a) of the  Indenture  is hereby  amended  and
restated in its entirety to read as follows:

         "The Company shall issue a press release with respect to any Repurchase
         Event and each  Repurchase Date and shall use  commercially  reasonable
         efforts to have such press release available on Bloomberg Business News
         (i) no later  than the date of  mailing of such  Company  Notice,  with
         respect to any such Repurchase Event, and (ii) no later than sixty (60)
         calendar days prior to each Repurchase Date."

         4.  Amendment to Note.  In each place in the Notes and the Form of Note
where the dates "March 26, 2011, March 26, 2016 and March 26, 2021" appear, such
reference and dates shall be changed to "March 26, 2011,  March 26, 2015,  March
26, 2016, March 26, 2019, March 26, 2021 and March 26, 2023".

         5.  Concerning  the Trustee.  The Trustee  accepts the amendment of the
Indenture  effected  by this  Supplemental  Indenture  and agrees to execute the
trust created by the Indenture,  as supplemented by this Supplemental Indenture,
but  only  upon  the  terms  and  conditions  set  forth  in the  Indenture,  as
supplemented by this Supplemental Indenture, to which the parties hereto and the
Holders of the Notes agree from time to time and,  except as expressly set forth
in the Indenture, shall incur no liability or responsibility in respect thereof.
Without  limiting  the  generality  of the  foregoing,  the  Trustee  assumes no
responsibility for the correctness of the recitals herein contained, which shall
be taken as the statements of the Company.  The Trustee makes no  representation
and shall have no  responsibility  as to the  validity  or  sufficiency  of this
Supplemental Indenture.

         6.  Miscellaneous.

             (a) Except as hereby  expressly  amended,  the  Indenture is in all
respect  ratified and confirmed  and all the terms,  provisions  and  conditions
thereof shall be and remain in full force and effect.

             (b) THE  INTERNAL LAW OF THE STATE OF NEW YORK  (INCLUDING  SECTION
5-1401 OF THE GENERAL  OBLIGATIONS LAW OF THE STATE OF NEW YORK) WILL GOVERN AND
BE USED TO  CONSTRUE  THIS  SUPPLEMENTAL  INDENTURE  WITHOUT  GIVING  EFFECT  TO
APPLICABLE  PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF
THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

             (c)  All  agreements  of the  Company  and  the  Guarantor  in this
Supplemental  Indenture  shall  bind  each  of its  respective  successors.  All
agreements  of the  Trustee  in  this  Supplemental  Indenture  shall  bind  its
successors.

             (d) If and to the extent that any  provision  of this  Supplemental
Indenture  limits,  qualifies  or  conflicts  with  another  provision  which is
required to be included herein or in the Indenture by the Trust Indenture Act of
1939, as amended, such required provision shall control.

             (e) The titles and  heading of the  sections  of this  Supplemental
Indenture are for convenience only and shall not affect the construction hereof.

                                       2
<PAGE>

             (f) This  Supplemental  Indenture may be executed in  counterparts,
each of  which  shall  be an  original;  but such  counterparts  shall  together
constitute but one and the same instrument.

             (g) In case any provision of this  Supplemental  Indenture shall be
invalid, illegal or unenforceable,  the validity, legality and enforceability of
the  remaining  provisions  hereof or of the  Indenture  shall not in any way be
affected or impaired thereby.

                            [Signature Page Follows]

                                       3
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this First
Supplemental Indenture to be duly executed all as of the date first above
written.

                                           ELECTROGLAS, INC.

                                           By: /s/ Thomas E. Brunton
                                               ---------------------------------
                                           Name: Thomas E. Brunton
                                           Title: Chief Financial Officer

                                           ELECTROGLAS INTERNATIONAL, INC.

                                           By: /s/ Thomas M. Rohrs
                                               ---------------------------------
                                           Name: Thomas M. Rohrs
                                           Title: Chief Executive Officer

                                           THE BANK OF NEW YORK TRUST
                                           COMPANY, N.A.,
                                            as Trustee

                                           By: /s/ Raymond Torres
                                               ---------------------------------
                                                     Authorized Signatory

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]